Boston Trust Walden Corp - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 252 filers reported holding BIO-TECHNE CORP in Q1 2016. The put-call ratio across all filers is - and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Boston Trust Walden Corp ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q1 2019$10,168,000
-35.3%
51,210
-52.8%
0.14%
-44.8%
Q4 2018$15,711,000
-48.2%
108,563
-27.0%
0.25%
-40.2%
Q3 2018$30,343,000
+32.6%
148,660
-3.9%
0.42%
+24.4%
Q2 2018$22,879,000
+10.1%
154,640
+12.4%
0.34%
+6.7%
Q1 2018$20,773,000
+10.2%
137,529
-5.5%
0.32%
+14.1%
Q4 2017$18,853,000
+5.1%
145,530
-1.9%
0.28%
-1.1%
Q3 2017$17,939,000
+26.2%
148,393
+22.6%
0.28%
+22.4%
Q2 2017$14,218,000
+13.6%
121,008
-1.7%
0.23%
+16.9%
Q1 2017$12,517,000
-55.4%
123,141
-54.9%
0.20%
-12.2%
Q4 2016$28,048,000
+80.2%
272,766
+91.9%
0.22%
-13.6%
Q3 2016$15,565,000
-3.3%
142,143
-0.4%
0.26%
-6.5%
Q2 2016$16,095,000
+18.6%
142,724
-0.6%
0.28%
+16.5%
Q1 2016$13,572,000
+55.2%
143,587
+47.8%
0.24%
+45.7%
Q4 2015$8,745,000
-30.9%
97,162
-29.0%
0.16%
-23.2%
Q3 2015$12,650,000
-10.1%
136,815
-4.2%
0.21%
-1.4%
Q2 2015$14,065,000
-5.7%
142,832
-4.0%
0.21%
-3.2%
Q1 2015$14,914,000
-9.4%
148,711
-16.5%
0.22%
-9.8%
Q4 2014$16,464,000178,1790.24%
Other shareholders
BIO-TECHNE CORP shareholders Q1 2016
NameSharesValueWeighting ↓
Ownership Capital B.V. 840,131$363,810,0004.80%
Montanaro Asset Management Ltd 89,950$38,952,0004.80%
Sandhill Capital Partners LLC 109,939$47,608,0004.09%
Brown Capital Management 918,328$397,673,0003.96%
STONE RUN CAPITAL, LLC 22,325$9,668,0003.57%
DF DENT & CO INC 686,484$297,275,0003.42%
Westwind Capital 27,741$12,013,0003.23%
MAIRS & POWER INC 657,962$284,924,0002.87%
Summit Creek Advisors LLC 58,133$25,174,0002.85%
Pembroke Management, LTD 76,250$33,019,0002.76%
View complete list of BIO-TECHNE CORP shareholders